![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Scheubeck, Gabriel 
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology, Bd. 103: S. 2373-2380
[PDF, 1MB]
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology, Bd. 103: S. 2373-2380
[PDF, 1MB]
Zimmermann, Heiner; Babel, Nina; Dierickx, Daan; Morschhauser, Franck; Mollee, Peter; Zaucha, Jan M.; Dreyling, Martin H.; Dührsen, Ulrich; Reinke, Petra; Verhöf, Gregor; Subklewe, Marion; Hüttmann, Andreas; Tousseyn, Thomas; Bachy, Emmanuel; Hauser, Ingeborg A.; Tarella, Corrado; Van den Neste, Eric; Gheysens, Olivier; Anagnostopoulos, Ioannis; Leblond, Veronique; Riess, Hanno; Choquet, Sylvain und Trappe, Ralf U.
(2018):
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
In: Transplantation, Bd. 102, Nr. 11: S. 1914-1923
[PDF, 0B]
Trappe, Ralf U.; Dierickx, Daan; Zimmermann, Heiner; Morschhauser, Franck; Mollee, Peter; Zaucha, Jan M.; Dreyling, Martin H.; Dührsen, Ulrich; Reinke, Petra; Verhoef, Gregor; Subklewe, Marion; Hüttmann, Andreas; Tousseyn, Thomas; Salles, Gilles; Kliem, Volker; Hauser, Ingeborg A.; Tarella, Corrado; Neste, Eric van den; Gheysens, Olivier; Anagnostopoulos, Ioannis; Leblond, Veronique; Riess, Hanno und Choquet, Sylvain
(2017):
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
In: Journal of Clinical Oncology, Bd. 35, Nr. 5:
536-+